Pharmacotherapy and Intensive Treatment of Drug Abuse - 1

This study has been completed.
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
VA Office of Research and Development
Information provided by (Responsible Party):
University of Kansas Medical Center
ClinicalTrials.gov Identifier:
NCT00000217
First received: September 20, 1999
Last updated: April 15, 2015
Last verified: April 2015
  Purpose
The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.

Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
Drug: Carbamazepine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacotherapy and Intensive Treatment of Drug Abuse

Resource links provided by NLM:


Further study details as provided by University of Kansas Medical Center:

Primary Outcome Measures:
  • Drug use
  • Effectiveness of medication
  • Level of pharm
  • Retention
  • Depression, anxiety

Study Start Date: September 1990
Primary Completion Date: October 1996 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000217

Locations
United States, Missouri
University of Kansas
Kansas City, Missouri, United States, 64128
Sponsors and Collaborators
University of Kansas Medical Center
National Institute on Drug Abuse (NIDA)
VA Office of Research and Development
Investigators
Principal Investigator: William Haning, M.D. University of Kansas Medical Center
  More Information

Publications:
J Addictive Dis. 13; 1994

Responsible Party: University of Kansas Medical Center
ClinicalTrials.gov Identifier: NCT00000217     History of Changes
Other Study ID Numbers: NIDA-06954-1  R18DA006954  R18-06954-1 
Study First Received: September 20, 1999
Last Updated: April 15, 2015
Health Authority: United States: Federal Government

Keywords provided by University of Kansas Medical Center:
drug abuse

Additional relevant MeSH terms:
Disease
Substance-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Carbamazepine
Anticonvulsants
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 25, 2016